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Abstract--A physiological f ow model was developed for  the elimination of Warfarin 
and Adriamycin in the rat. The model uses organ mass or volume, blood flow to the 
organ and tissue to plasma drug distribution ratios to compute unsteady state concen- 
tration profiles for each drug. The parameters in the model can be changed to match 
changes that could, occur in liver disease, aging or the influence of coadministered drugs 
used for other therapeutic purposes, Elimination rates may be reduced by liver damage, 
reduced liver function, altered circulation rates or altered tissue binding resulting from 
disease or aging. Coadministered drugs could inhibit the elimination of the primary drug 
via competition for a common site, or could also diminish elimination by producing 
liver damage. Drug elimination could be enhanced by enzyme induction. These effects 
have been studied experimentally and simulated using computer programs. 
1. INTRODUCTION 
Body functions are very flexible processes and are able to adapt to a variety of external 
and internal stimuli. Such responses can occur at biochemical levels, ~hich in turn are 
expressed in the physiological processes of an organ. One organ can affect others, which 
in a chain of events is ultimately manifested at the level of the ~vhole animal. Disease can 
perturb one or more of these steps and these results take on man} forms[l]. The treatment 
of disease often requires drug administration. In many cases, a multiple combination of 
drugs is required for different therapeutic purposes. Drug therapy should be based upon 
a synthesis of biochemical, anatomical, physiological, pathological and pharmacological 
knowledge. Such a synthesis can be greatly aided by mathematical modeling. Modeling 
has the promise for great advances in knowledge in the biomedical fields[2. 3]. By com- 
puting the overall results, simulations can provide an understanding of a combination of 
abstract equations and help illuminate the complex interrelationships bet~veen the organs 
of the body, disease, age and multiple drug therapy. 
The liver has been described as a chemical factory, it can synthesize proteins such as 
serum albumin which can avidly bind many natural substances and drugs. In its role as 
a chemical factory, the liver is also the site of metabolism of man',' natural substances for 
energy, or detoxification of endogenous and exogenous ubstances for excretion via the 
bile. In liver disease reduced synthesis of serum albumin can cause hypoalbuminemia. 
This alters the distribution of endogenous ubstances as well as drugs among tissues of 
the body. In this report we will focus on the liver, and how diseases of the liver can affect 
liver function and consequently drug therapy. Our models will pertain to the effects of 
liver damage on drug distribution, metabolism and excretion. 
++ Computer listing available. 
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2. POLYEXPENENTIAL AND PHYSIOLOGICAL FLOW MODELS 
Drug elimination kinetics have been described by polyexponential models (PEM) for 
several decades in the form 
n 
Cp = ~, Ai e-k" (1) 
i=1  
Cp designates the concentration of a drug in the plasma at time t; i = the compartment 
number; Ai = the coefficient for the compartment; ki is a hybrid rate constant for the 
SCHEME EQUATIONS 
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Fig. 1. Block diagram and equations for the Physiological Flow Model for the elimination of Adriamycin. The 
following symbols are used: g(t) = injection, C = concentration. Q = blood flow. R = tissue to plasma 
concentration ratios. Subscripts. p = plasma, M = muscle, S = skin, K = kidney. MR = marrow. G = gut. 
rB = tight binding compartment, L = liver, rL = rate of elimination in bile, k~ and k,_ = rate constants for 
the tight binding compartment, tau. r~.:.3 are for lag periods in the bile duct. (Permission has been granted by 
the authors and Elsevier Biomedical Press to republish this figure). 
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transfer between compartments. Most often two compartment models can adequately 
represent experimental data. Infrequently, three compartments may be required; more 
are very rarely seen. Polyexponential models have been very useful for many applications 
including uses in human clinical pharmacokinetics and pharmacology. However, they have 
some inherent limitations: 
(I) They are theoretically restricted to systems that can be described by linear differential 
equations which often is not the case in animals. 
(2) The compartments are abstract and do not correspond to actual anatomical organs 
or tissue. 
(3) The rate constants pertain to transport rates between abstract compartments rather 
than physiologically meaningful compartments. 
The mammalian body also can be modeled as an open system consisting of numerous 
organs which are interconnected by the circulatory system. In contrast with the PEM the 
Physiological Flow Model (PFM) utilizes (1) organ masses or volumes (V), (2) blood flow 
to the organs (Q) and t3) the tissue to plasma distribution ratios (R) for a drug (Fig. 1). 
The PFM consists of differential equations describing various organs and tissue regions 
in the body where the drug is exchanged and stored. These differential equations are 
solved simultaneously to find drug concentration as a function of time. Such models are 
more complex than most currently used in pharmacokinetics but are in fact relatively 
simple compared to other areas of simulation (e.g. chemical factories, flight training sim- 
ulators, etc.). 
Some of the mathematical relationships between the PEM and PFM models have been 
described previously[4]. Although the PFM model is more formidable to develop it pro- 
vides much valuable information. Some of the key parameters in the PFM can be changed 
in accord with disease or the coadministration f another drug[5-8]. The resulting infor- 
mation concerning concentration i  various organs is important in rational drug therapy. 
The goal is to provide suitable concentrations of drug for therapy to be effective while 
avoiding toxicity resulting from (1) too high a concentration of drug in an organ which is 
(or is not) the site of action or (2) too much drug in an organ for too long a period of time. 
3. PHARMACOLOGICAL PROPERTIES OF WARFARIN AND ADRIAMYCIN 
We have conducted experimental studies of elimination rates with two medically useful 
drugs, viz. warfarin and Adriamycin. Warfarin is an anticoagulant which is used to prevent 
the clotting of blood by inhibiting a key step in the synthesis of four clotting factors. The 
site of action as well as that of its metabolism and elimination is the liver. Adriamycin is 
an antineoplastic drug widely used for the treatment of a variety of tumors. One common 
feature of these two drugs is that both are metabolized in the liver and excreted in the 
bile. The kinetics of elimination can be observed by collection and analysis of bile. These 
drugs do, however, have one marked pharmacological difference. Warfarin is avidly bound 
but in a reversible fashion by serum albumin, whereas adriamycin disappears rapidly from 
the plasma and is distributed to tissues. Any occurence of reduced albumin synthesis 
(hypo-albuminemia) results in decreased binding of drugs like warfarin which are tightly 
bound by serum albumin. 
Adriamycin is noted for its toxicity in the heart, gut and bone marrow. Thus it is useful 
to include these organs in the model. Adriamycin is also extremely reactive forming co- 
valent or almost irreversible bonds with tissue components[9], and this property must 
also be reflected b,v the model, Thus, while warfarin and Adriamycin have some phar- 
macological features in common, there are also some differences which must be taken 
into consideration i model building. 
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4. MODEL FORMULATION 
Physiological models should include the following: (1) the tissue regions which are the 
pharmacological site of action, (2) organs which are the site(s) of metabolism or excretion, 
(3) organs which are sites of toxicity and (4) organs which accumulate the drug and must 
be considered in the mass balance of the drug i Fig. I). 
4.1. Components of the model 
4. I. 1. Volume. The volume (V) or mass of most of the organs in the model is computed 
on the basis of allometric Eqs. (2, 9) of the form 
y = aM b. (2) 
in which Y is a physiological or anatomical variable, M is the mass of the body and a is 
a constant, For example, the volume of the liver is calculated by 
liver volume = 34W °'s7. (3) 
where W = body mass. Volumes are used for the organs rather than mass since the tissue 
concentrations are in volumetric terms. The volumes of the other organs in the model are 
computed using similar relationships with different exponents and coefficients[5-7]. For 
example, for a 234-g rat the values in ml are plasma, 10.45: muscle, 117: gut 12.5; kidney 
2.15; liver 9.6; and skin, 38.8, The volume of the marrow is based upon experimental 
values reported from various sources[10]. The concentration f drug in the liver and other 
organs is assumed to be uniform, as in a homogeneous reactor. Future models could 
incorporate nonuniform binding by intracellular f actions. 
4.1.2. Bloodflow. The blood flow (Q) to each organ also is based on reported cor- 
relations[2, 5-7] and is calculated in a fashion similar to that for the volume. For example, 
blood flow to the liver is computed by the following: 
Qt_ = 26.6w °875 (4) 
where Qz, = blood flow to liver (ml/min). The calculated blood flow to other organs in 
ml/min was muscle, 3.45; gut, 6.08; kidney, 5.75; liver, 7.46; and skin, 0.28. Rapid dis- 
tribution of a drug is assumed to occur between the tissue and plasma circulating through 
it. The concentration f drug in the plasma leaving an organ is assumed to be in equilibrium 
with that drug in the tissue. 
Blood flow to the liver can be altered by obstruction or certain drugs which affect blood 
flow. The clearance of a drug by the liver is especially important with drugs which have 
a high first pass effect. A high fraction of such drugs passing through the liver is removed 
in transit leaving little if any for distribution to the remainder of the body. 
4.1,3. Tissue to plasma partition ratio. The tissue to plasma distribution ratio (R) 
varies with the drug. It can not be predicted and must be measured experimentally for 
each drug. For example, some drugs cannot cross the blood brain barrier, and thus little 
if any reaches that tissue. For Adriamycin, muscle and skin have low binding values, 4.27 
and 5.75, respectively, while the sites of toxicity, marrow and heart, have high values of 
47.74 and 32.17, respectively[10]. 
In physical terms, the binding ratios R represents a competitive balance between bind- 
ing sites on serum proteins and intracellular binding sites[11]. The binding ratio depends 
Aspects of disease and drug therapy 1129 
not only on the chemical affinity of sites but also on the concentration of each protein 
which contain the binding sites. For example, Warfarin is bound by various subcellular 
fractions but to the greatest extent by the soluble traction in the liver[Ill. Disease can 
affect the concentration of albumin and also the soluble fraction in liver which will thus 
affect RL. The concentration of glutathione-S-transferase, which is in the soluble fraction 
and binds many substances, can be altered by thyroid disease and drugs such as pheno- 
barbital[13], which can change the R value. The value of the binding ratio can be altered 
accordingly as input data in the program. 
The competition between serum albumin and tissue components also has been dem- 
onstrated in vitro at an intermediate l vel of complexity with isolated hepatocytes[12]. 
The competition between serum albumin and the soluble fraction for warfarin has been 
studied in vitro using three compartment dialysis cells with HSA in one of the end com- 
partments and the soluble fraction in the other compartment[l l]. The central compartment 
serves to measure unbound warfarin which is in mutual equilibrium with all of the binding 
sites on all of the proteins. Dialysis cells also have been used in competitive displacement 
studies of the redistribution of warfarin when combinations of drugs and free fatty acids 
are involved which compete for shared binding sites on serum albumin and the soluble 
fraction of liver. 
4.1.4. Enzymatic parameters. Drugs are metabolized by enzymes in the liver (and 
some other tissues). Enzyme kinetics can be described by the Michaelis-Menten equation. 
If coadministered drugs share a common step in their uptake, metabolism or elimination. 
there may be a competition for the binding site(s) resulting in a mutual inhibition. Drug 
metabolism and its inhibition will conform to one or more equations typically found in 
enzyme kinetics. The enzyme parameters for drug metabolism in vivo may differ from 
those obtained in vitro because of intracellular binding which will alter the concentration 
of the drug at the site of metabolism. Furthermore, the concentrations involved in con- 
jugation reactions, such as with glutathione, may be optimal for assay purposes in vitro 
but not so for metabolism in vivo. The apparent K,,,'s and Vm~x's for warfarin and Ad- 
riamycin were estimated through the model from experimental e imination data using a 
least squares fitting procedure. However, the word "'apparent" must be stressed, because 
in vivo more than one enzyme may be involved. 
The kinetic elimination rate is assumed to follow the Michaelis-Menten equation: 
Vrrlax 
rL = (5) 
[ + Km/[S]"  
in which rc represents the observed rate of excretion of the drug, [S] the substrate con- 
centrations, K,,  the apparent dissociation constant of the enzyme substrate complex. V,,~ 
represents the maximal elimination velocity. Vmax often cannot be measured experimen- 
tally because of drug toxicity at high concentrations required for saturation of the enzyme. 
In regressive determinations of Vmax, there are usually high interrelations with K .... Liver 
disease or experimentally produced liver damage can alter the concentration of a key 
enzyme(s) in the liver which would be manifested by a reduction in the ~,~a.,. 
Multiple metabolites of drugs are often formed. In modeling drug elimination it is often 
necessary to incorporate multiple pathways either in parallel or in sequence. At least four 
hydroxylated metabolites of warfarin plus an unidentified conjugate have been re- 
ported[14]. We have incorporated two pathways into the warfarin model[5-7]. The K,,, 
for Warfarin determined by parameter optimization in vivo was about 65 ~.mole/L. This 
is in the same range as the K,,, reported for several metabolites of warfarin in vitro with 
microsomes which ranged from 30 to If0 txmol/L[14]. The V ..... estimated from the in 
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vivo data was 0.075 x 10 -9  mole/min-g liver which was much lower than that obtained 
in vitro. The difference, in part, could be due to the fact that in vivo a great deal of the 
warfarin is bound by the soluble fraction of rat liver[11]. 
Other drugs which are coadministered with Warfarin for other therapeutic purposes 
and which are metabolized in the liver could compete with binding sites in the liver thus 
acting as inhibitors of elimination. The equations which we used for competitive inhibition 




1 + K~s/[S] + (K~s/[S]) ( [B] /K~B) '  
Vma~B 
I + K,,B/[B] + (KmB/[B])([S]/Kr~s)" 
rs is the measured rate of elimination of substance S (Warfarin), and rB is the measured 
rate of elimination of substance B (BSP). The degree of inhibition is related to the dis- 
sociation constants and the concentration of the drugs. These equations result from 
straightforward derivations of site competition between two drugs which individually fol- 
low Michaelis-Menten kinetics cited above. The parameters in the interaction equations 
are identical with those determined in the individual noninteracting drug systems. 
Other drugs or even a reactive metabolite can interact irreversibly with an enzyme 
forming an inactive enzyme. In the model, this would correspond to a decrease in the 
Vmax. Adriamycin forms a free radical which is extremely reactive[9, 15] and can adversely 
affect drug metabolism in this way. The consequences of a reduced rate of metabolism 
would be an increase in the concentration of a drug in tissue as time progressed, This 
feature would be most significant for drugs such as the antineoplastics which have a narrow 
margin of safety. For irreversible binding, the duration of the effect would be related to 
the half-life of the affected enzymes. For example, thioacetamide r duced the concen- 
tration of hydroxylases which metabolized warfarin[16]. The half-life of these enzymes 
ranged from about 16 to 35 h. 
Adriamycin also reacts covalently and almost irreversibly with various macromole- 
cules[9, 15]. The current model incorporates a lumped tight compartment using empirically 
determined parameters [kl and k,., Eq. (8) in Fig. 1] to represent the rate of formation of 
the covalent bonds in various tissues and the subsequent slow rate of return to the plasma. 
Enzyme inducers can increase the concentration of drug metabolizing enzymes. Other 
inducers can also increase the mass of the liver and the blood flow to the liver. Accelerated 
metabolism of drugs can decrease the effectiveness of therapy unless the dose is adjusted 
accordingly. Similar alterations can be made to the parameters in the model[4]. We have 
successfully modeled simple reversible competition[5-7], induction by phenobarbital nd 
liver damage produced by carbon tetrachloride[4]. 
Another point which should be kept in mind for modeling is that in addition to inhibition 
of key enzymes there may be depletion of key substrates involved in drug metabolism 
which also would reduce the rate of drug metabolism. For example, Adriamycin and other 
substances such as n-ethylmaleimide and diethylmaleimide can deplete glutathione which 
is involved in conjugation reactions. 
4.1.5. Bileflow. Many drugs are excreted in the bile, often in the form of metabolites. 
We have developed very sensitive procedures to measure the kinetics of excretion of 
several drugs in the bile of a rat in the absence of other drugs or disease. Such kinetic 
data has been used for the development and testing of a PFM for warfarin[5-7] and 
Adriamycin[10]. Bile flow rate (r) is determined experimentally in the anaesthetized rat. 
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Under the usual experimental conditions the flow of bile is quite uniform over a period 
of hours. The flow rate can be reduced by disease, liver damage or obstruction, and can 
be increased experimentally by choleretic agents or inducers of the mixed function oxi- 
dases in the liver. The bile flow rate can be changed in the model in accord with the 
experimental or assumed physical conditions. 
5. EFFECTS OF LIVER DISEASE ON THE MODELS 
Liver disease can take various forms such as hepatitis, cirrhosis and cancer which can 
affect the uptake of drugs and other substances by the liver, and also their metabolism 
and elimination in the bile[l]. These conditions can be simulated with the model by varia- 
tions of one of several of the parameters which represent he physiological functions that 
can be affected by disease or the coadministration of other drugs (Table 1). For example, 
the enzyme Glutathione-S-transferase, which is contained in the soluble fraction of rat 
liver, is capable of binding a variety of endogenous and exogenous ubstances, and is 
considered to play a role in the uptake of drugs by the liver[ 13]. The concentration of the 
enzyme can be altered by surgery' (thyroidectomy, orchidectomy) and various chemical 
inducers. The PFM copes with such changes by altering the binding ratio in the liver RL 
(Fig. 1). Figure 2 shows the results of computer simulations in which RL was varied. 
Quantitative confirmation of such results is not currently available. However, the pre- 
dicted reduction of concentration in the bile is seen to vary' in a nonlinear fashion with 
decreasing Re. 
Table I. Changes in values to simulate disease 
Equation Parameter Condition 
II) QH Clot or thickening can obstruct or reduce blood 
flow 
Rn Reduced binding from disease or age 
/2) Cp Reduced concentration of protein, e.g. 
hypoalbuminemia 
Vp Blood loss from hemorrhage 
13) !, '~r Cachexia, amputation 
Rw Aging 
(4) Qs Burns 
(5) Vx Aging. disease, toxicity 
QK Drugs (dilators or constrictors), obstruction 
Rx Aging 
kx Aging. disease, toxicity 
(6) R.ttR Damage from drugs 
(7) Vo Damage, surgery 
(8) k~ Concentration of endogenous protective agents 
by GSH 
k: Slow dissociation, repair, resynthesis 
(9) !/~. Liver damage, surgery 
Qt. Drugs. obstruction, disease 
Rt Drugs and aging which affect concentration of 
ligandin 
rt, (a) Endogenous or exogenous ubstances 
~hich share steps in elimination acting as 
inhibitors 
lb) Drugs which act as inducers 
Ic) Drugs or toxic substances which affect 
drug metabolism 
Id) Disease which affects normal processes of 
elimination of endogenous ubstances 
(e.g. bilirubin) or drugs 
I I0) rl._-.3 Obstruction of bile duct 
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results only  for the excret ion  in the bile. 
Very often the treatment of disease involves the coadministration of several drugs for 
different therapeutic purposes. If some of the drugs should share one or perhaps more 
steps in either their uptake, intracellular distribution, or metabolism, there may be a mutual 
competition for a site(s), If the competition involves a rate-limiting enzyme in the me- 
tabolism of the substance mutual inhibition will result (see Section 4.1.4). Such compe- 
tition could alter the rate of elimination and the concentration times time (C x t) profile 
could affect therapy or result in toxicity. Thus comprehensive models for the treatment 
of disease should be able to describe 
(1) the effects of disease on basic physiological processes, 
(2) the effects of multiple drug therapy not only upon basic physiological processes, but 
diseased physiological processes, as well[17]. 
The PFM has sufficient potential and flexibility to cope with these multiple complex- 
ities. Our experimental studies in testing such models have involved chemically induced 
rather than spontaneous pathology. The classic hepatotoxin CCI4 was used because it can 
be controlled within limits, (e.g. mild, moderate, severe}, and can be reproduced exper- 
imentally to accumulate adequate sample sizes. For (his substance there has been con- 
siderable research into the underlying biochemical basis of the pathology. For example. 
treatment with CCIa produces liver damage which results in reduced rate of elimination 
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of Warfarin and Adriamycin in the bile. One major feature of CC[., toxicity is damage to 
the microsomes which are invob,ed in drug metabolism. 
6. COMPUTER PROGRAMS OF THE MODELS 
Computer programs were developed to simulate the elimination of warfarin in the rat 
as well as for interactions between it and some other drugs[5-7}. The Warfarin model 
was later modified and expanded for Adriamycin[ 10] elimination by adding compartments 
/'or the heart, the bone marrow and a tight binding compartment for almost irreversible 
binding of Adriamycin. Acute and chronic drug interactions as well as liver damage can 
be simulated by changing the value of parameters in both programs. Both programs can 
handle repeated administration of a drug as well as continuous infusion of a drug. 
Adaptation of animal models for human application raises the question of model va- 
lidity. There is. of course, much similarity in organ physiology and function among mam- 
malian species. There have been various reports concerning scale up of results from small 
to large animals. The chemical partitioning appears to scale up well[9]. But genetic dif- 
ferences in the genes involved the types and rates of drug metabolism in different species 
requires appropriate adjustment in these parameters. 
7. AGING 
While aging is not to be construed as a disease it does cause a reduction of many 
physiological functions[18]. Some of these changes are important components of an in- 
tegrated model for disease and drug therapy. The reductions in physiological function can 
be taken into consideration by changes in parameters which are in the flow model. For 
example, the rate of drug metabolism by the liver also is reduced in aged animals. 
The flexibility of the PFM permits one to simulate the consequences of a change in 
one or several of the parameters in the model. Conway et a/.[19] reported a reduction of 
binding of warfarin by liver, muscle and kidney in very old rats. These results were 
converted to R values and used in the warfarin model to simulate the effects of age on 
the distribution and elimination of warfarin. Computations were carried out for the period 
of 5 to 120 rain. For conciseness only the values calculated for the 120-min time period 
are presented (Table 2). Drug concentrations are shown for binding ratios determined in 
360-day-old rats tcontrols) as compared to those simulated for binding ratios in 832-day- 
old rats. Note the subtlety of the changes v,'hich are elucidated by changing only one R 
Table 2. The effect of varying tissue to plasma ratios resulting from aging on 
the concentration f Warfarin (nmole ml '1 
Decrease 
R,. to 6--~.' .~. 
Decrease Decrease Decrease R~,- to 73~ 
Tissue Control R,,- to 73~:' RL to 64% R~t to 59~ RM to 59"~ 
Plasma 19.2 19.3 21.2 20.5 23.0 
Liver 20.7 20.8 14.6 22.1 15.9 
Bile 20.2 20.3 17.1 20.8 17.9 
Muscle 1.2 1.2 1.2 0.7 0.8 
Kidney 9.2 5.7 10.2 9.8 8.1 
Gut 4.6 4.6 5.1 4.9 5.5 
Skin 5.5 5.5 6.1 5.9 6.6 
~' The standard R values ~ere reduced by the indicated % which are based 
upon the values of 832-day-old rats as c~: 360-day-old male Sprague-Da~le~ 
rats. 
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value at a time as well as the combined effect of changing all three R values. One of the 
values of the PFM is to be able to display such results that would be very difficult if not 
impossible to obtain experimentally. 
8. MULTIFACTORIAL EFFECTS 
The interactive ffects of changing several factors simultaneously on the distribution 
and elimination of a drug can also be simulated. For example, one can alter the blood 
flow, increase or reduce tissue binding, increase or reduce drug metabolism and simul- 
taneously study the effects of other drugs as inhibitors or inducers on the distribution and 
elimination of a drug (Fig. 1 and Table I). Powerful new computers with graphics capa- 
bilities can readily achieve such simulations attained to better determine and illustrate 
the interrelationships between disease, drug therapy and aging. 
9. DISCUSSION 
Disease can take many forms with varying degrees of severity, and often with the 
involvement of multiple systems in the body. Such complexity requires complex models 
such as the physiological flow model. 
The physiological f ow model has a number of qualities that make it useful for these 
studies: 
(1) Flexibility: The flexibility of the model is a prime advantage permitting one to study 
many of the changes that occur within the body as a result of external stimuli (en- 
vironmental changes, chemical exposure or pathogens) or internal stimuli, or com- 
binations of both. 
(2) Integration: The ability to integrate information from various sources: biochemical, 
anatomical, physiological, pathological nd pharmacological. 
(3) Tissue concentration: The ability to predict the concentrations of drugs at sites of 
action or toxicity. 
(4) Interactions: The ability to simulate the consequences of drug-disease and drug- 
drug interactions. 
(5) Complex behavior: The ability to simulate and predict complex, nonlinear or unusual 
behavior. 
(6) Multiple effects: The ability to perturb the individual components of complex situ- 
ations and to quantify the individual contributions as well as the ability to perturb 
multiple components to determine their combined effects on different organs and 
their function. 
(7) Pathology: The ability to elucidate the effects of pathology of an organ, such as the 
liver, on drug elimination, the residence time of drugs in various tissues and the 
consequences of such changes on distribution and elimination of a drug. 
The current models are by no means final, definitive products, but the results obtained 
to date point to their usefulness. With the availability of powerful new personal computers 
at more modest prices than were available in the past, the feasibility of developing complex 
models for testing and simulation is greater than ever before. Furthermore, in recent years 
many new and sensitive assays have been developed for measuring the concentration of
drugs in the plasma of man which permits sensitive testing of models. 
Adjusting drug dosages i especially important with drugs with narrow margins of safety 
such as the antineoplastic drugs. Toxicity with these drugs is especially great. It often 
depends not only on the concentration i  sensitive tissues but also on the residence time 
of the drugs in those tissues. Both of these can be affected by liver or kidney disease and 
the coadministration f other drugs. 
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Physiological f ow models offer the potential of making rational drug therapy more 
feasible than ever by integrating our biochemical knowledge of drug metabolism, our 
physiological knowledge of biliary and urinary excretion and our pharmacological knowl- 
edge of drug elimination and the effects of other drugs and disease on these processes. 
The PFM which have been developed to date show the potential for future models. Ul- 
timately, the PFM can be used to simulate the consequences of various changes (e.g. 
disease, other drugs) and also to provide more quantitative changes in dosage to optimize 
therapy and minimize the risk of toxicity. 
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